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Abstract
OBJECTIVE:
Fatigue is common and burdensome in ANCA-associated vasculitis (AAV). This study aimed to 
understand how fatigue changes over time following treatment initiation and determine whether 
individuals with the poorest prognosis can be robustly identified.
METHODS:
149 patients with AAV and new onset disease recruited to two clinical trials (RITUXIVAS and MYCYC) 
were followed for 18 months.  Fatigue was measured at baseline and 6 monthly intervals using the 
vitality domain of the SF-36 quality of life questionnaire and compared to a cohort of 470 controls. 
Group-based trajectory modelling (GBTM) determined trajectories of the symptom between which 
baseline characteristics and on-going fatigue scores were compared.
RESULTS:
Fatigue levels at diagnosis were worse in patients than controls (median 30 IQR 10, 48 vs 70 IQR 55, 
80; p<0.001), with 46% of patients reporting severe fatigue. Fatigue improved after 6 months 
treatment but remained worse than controls (p<0.001). GBTM revealed varied trajectories 
of fatigue: low fatigue stable (n=23), moderate baseline fatigue improver (n=29), high baseline 
fatigue improver (n=61) and stable baseline high fatigue (n=37). Participants who followed stable 
high fatigue trajectories had lower vasculitis activity compared to improvers but no other 
demographic or clinical variables differed.
CONCLUSION:
This study longitudinally measured fatigue levels in patients with AAV.  Although, most patients 
improve following treatment, an important subgroup of patients report persistent high levels of 
fatigue that does not change. Few clinical or laboratory markers distinguished these patients, 
suggesting alternative interventions specific for fatigue are required.
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Trial registration
RITUXVAS EudraCT Number: 2005-003610-15 registered 27/9/05
MYCYC EudraCT Number: 2006-001663-33 Registered 21/12/06
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Earlier recognition and the successful introduction of immunosuppressive regimens to treat ANCA-
associated vasculitis (AAV) have transformed the outcome of these life threatening diseases(1). 
Mortality rates have been reduced to 20% at 5 years, however relapses and chronic damage are now 
dominate patient outcomes  (2). Reduced quality of life remains common despite disease remission 
and successful control of the inflammatory process (3). Previous studies have identified fatigue as 
the most significant determinant of poor quality of life for patients with AAV with more than 90% of 
patients reporting fatigue to be the most important limiting factor (4-6).  Fatigue in AAV has also 
been linked to reduced social participation, social withdrawal and unemployment (7, 8). However, 
little is known about the longitudinal nature of this important symptom as all previously published 
studies investigating patients with AAV and fatigue have been cross-sectional in nature. 
Our previous cross-sectional studies in AAV have suggested fatigue is multi-factorial in origin (9, 10). 
Sleep disturbance, pain and inflammation, as measured by C reactive protein (CRP), were all 
associated with fatigue, although the association with inflammation was the weakest(10). In a 
further study of AAV patients in remission, fatigue was associated with heightened perception of 
exertion, depression, anxiety, and sleep disturbance suggesting that fatigue is of a central origin 
rather than originating due to problems with muscle or the cardiovascular system (9). Considering 
the multifactorial nature of fatigue it seems unlikely that the change over time of this complex 
symptom will be homogeneous; examining average change over time may hide variability in fatigue 
response to treatment. No previous studies have investigated change in fatigue longitudinally in AAV 
patients. This is supported  by recent findings  in patients with rheumatoid arthritis (RA) that suggest 
the experience of fatigue over time is not uniform; there are subgroups of patients in whom it 
improves while for others it remains a persistent problem despite treatment (11, 12). It is unknown 
whether this is also true for patients with AAV.  
The aim of this study was to describe the longitudinal experience of fatigue, following treatment 
initiation, in an inception cohort of patients with generalized AAV recruited to two clinical trials. It 
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sought to determine how fatigue responds to treatment at a group level, and whether important 
subgroups of patients could be identified, between whom fatigue response differs. Finally it aimed 
to characterise those who experienced the poorest fatigue prognosis. 
Methods
Patient population
Newly diagnosed patients with generalised AAV recruited to two European Vasculitis Study Group 
(EUVAS) clinical trials (RITUXVAS and MYCYC) between 2006 and 2011 were included in this study. 
Briefly, RITUXVAS compared rituximab plus 2 doses of cyclophosphamide for inducing remission with 
conventionally dosed pulse cyclophosphamide followed by azathioprine for maintenance 
therapy(13). MYCYC compared mycophenolate mofetil with pulsed cyclophosphamide for 3-6 
months until remission and then transferred to azathioprine for maintenance therapy(14). All 
patients received prednisolone, initially 1mg/kg body weight per day tapered to 12.5 mg per day at 
the end of month three and to 5mg per day by 18 months. 
For this study, patients who had completed at least two SF-36 health related quality of life 
questionnaires, including baseline were included; 33 RITUXVAS patients, 117 MYCYC patients. 
General population controls were identified from a UK commercial online sampling frame 
(www.192.com), a representative source shown to have >80% population coverage(15),and mailed 
an SF36 questionnaire. The sample was originally selected to be age and gender matched to a large 
UK AAV cohort(6).
Data collection
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MYCYC followed patients for 18 months while RITUXVAS followed patients for 24 months. For 
consistency, we used the 18 month time point as the end date for this study. The following data 
were collected at six-monthly intervals during the trials and used in this study; age, sex, clinical 
diagnosis (granulomatosis with polyangiitis vs microscopic polyangiitis), ANCA serology, disease 
activity measured using the Birmingham Vasculitis Activity Score 2003 (BVASv3), assessment of 
damage using the Vasculitis Damage Index (VDI), dialysis dependency and time to clinical remission 
(as defined in the original trial protocols, as the complete absence of clinical disease activity using 
the BVAS item list on two separate occasions and supported by a normal CRP concentration); 
laboratory data including serum creatinine concentration; CRP; treatment, defined by the induction 
regime (pulse cyclophosphamide, mycophenolate or rituximab), and the 36 item health related 
quality of life questionnaire Short Form Health Survey (SF-36).
The primary outcome for this study was change in fatigue as defined using the vitality domain of the 
SF-36. SF-36 contains 36 items that assess health related quality of life in eight health dimensions: 
physical functioning, role physical, bodily pain, general health, vitality, social functioning, role 
emotional, and mental health. The SF-36  has performed well in previous AAV studies(16) and has 
been endorsed as a core AAV outcome measure by Outcome Measures in Rheumatology 
(OMERACT)(17). SF-36 fatigue domain scores 4 items and is negatively scored with a range 0-100 so 
that lower scores indicate more fatigue. It has been shown to be a valid measure of fatigue(18, 19).
Ethics
The study was conducted in compliance with the Helsinki Declaration. The two trials were sponsored 
by Cambridge University Hospitals NHS Foundation Trust. Vifor Pharma (previously Aspreva 
Pharmaceuticals) provided a research grant to cover the trial and MMF costs for MYCYC and F. 
Hoffmann–La Roche provided the rituximab and a research grant that contributed to trial costs for 
RITUXIVAS. The trials received ethical approval from for MYCYC and  ethics committee of each 
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participating center and were conducted according to the European Union Clinical Trials Directive 
(Directive 2001 EU/20/EC), (EudraCT numbers, 2006-001663-33 and 2005-003610-15 the 
Oxfordshire Research Ethics Committee B (reference number 06/Q1605/120)).  Regulatory approval 
was obtained from the national regulatory authorities in each country. Written informed consent 
was obtained from each participant. The control data collection study was approved for conduct by 
the University of Aberdeen College of Life Sciences Ethics Review Board (ref: CERB/2010/1/493).
Statistics
Quantitative data is described as mean and standard deviation for normally distributed variables and 
median with interquartile range (IQR) for non-normally distributed variables. 
Differences in quantitative data were tested with student’s t test (with Welch’s correction for 
unequal variances if appropriate) or the Mann Whitney U test depending on data distribution. 
Differences in fatigue scores at each follow up were tested using the Kruskal-Wallis 1-way ANOVA 
test for non-normally distributed data. 
All statistical analyses were two-tailed.  A p value < 0.05 was considered statistically significant for all 
analyses. Clinically meaningful differences in fatigue were examined in reference to previously 
applied minimum clinically important difference (MCID) estimates(20-22). The MCID for fatigue was 
>10 units on the 0-100 SF-36 Vitality subscale.
Latent trajectories of fatigue change were identified using group-based trajectory modelling (GBTM).
GBTM is used to cluster individuals who show similar progressions of scores over time and can 
inform between-group comparisons of differences in outcome. We therefore applied GBTM to 
determine whether clusters of participants followed similar fatigue trajectories during follow-up. 
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Specifically, GBTM for censored normal data was used, as the SF-36 VT is a continuous scale, with a 
minimum value of 0 (maximum fatigue) and a maximum value of 100 (minimum fatigue). Initially, 
the existence of four plausible cubic trajectories was proposed. Trajectories were then added or 
removed in consultation with the model-fit statistics, and clinical interpretation of the model, until 
the best-fitting model was identified. The best-fitting number of trajectories is determined as the 
model with the lowest Bayesian Information Criterion (BIC), provided there is sufficient support for 
the complexity of a model. A model with additional trajectories was accepted if the log Bayes factor 
was greater than six (2loge(B10 ≥6)). Model fit was then further improved by specification of the 
correct order polynomial (e.g. liner, cubic, quadratic) for each trajectory. 
Characteristics of each GBTM group were defined using the data collected. Differences in fatigue 
scores at each follow up within the GBTM group and differences between the GBTM groups were 
analysed using Freidman’s test for repeated measures. Time to remission was analysed using Kaplan-
Meier survival analysis and log rank test. Differences in categorical data were analysed using Pearson 
2 test. Correlations were assessed using Pearson’s correlation.   Analysis of correlations between 
fatigue and disease severity, inflammation and creatinine were pre-specified before data collection.
The GBTM analysis was conducted using Stata 14.0 (College Station, TX), all other analyses were 
performed using SPSS Statistics Version 22 (IBM, Armonk, USA).
Results
Patient characteristics
One hundred and fifty patients with newly diagnosed AAV, of whom 117 of 140 patients were from 
the MYCYC trial and 33 of 44 patients were from the RITUXVAS trial, and 470 general population 
controls were included in the study. Controls were older than patients but there was no difference in 
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the sex ratio (table 1).  Patients had high levels of disease activity at baseline. There were no 
differences in the two trials when comparing the patients’ ages, diagnoses, disease activity scores at 
entry, CRP concentrations, or fatigue scores. Due to protocol differences related to the inclusion 
criteria, patients recruited to the RITUXVAS trial had worse renal function than those recruited to 
MYCYC trial (Creatinine RITUXVAS 310mol (114-443) vs MYCYC 109mol/l (75-177); p<0.001).
Fatigue change
Patients reported substantial levels of fatigue at diagnosis, which were worse than controls (table 1). 
The median fatigue score for patients was four times greater than the MCID [18-20] compared to 
controls (median 30 (IQR 10-48) vs 70 (IQR 55-80). 
The median fatigue level improved over the first 6 months with treatment (figure 1) but then 
remained stable with no differences between fatigue scores at 6, 12 and 18 months. One hundred 
and five patients (70%) reported a clinically significant improvement in fatigue between baseline and 
6 months following the start of treatment. The median change of improvers was 45 (IQR 30-60), 4.5 
times the MCID. However, despite improvement from baseline, the median fatigue score for the 
patient population remained worse at all time points compared with healthy controls (Figure 1). 
Despite the median change analysis suggesting improvement in fatigue scores this concealed 
important differences in the longitudinal pattern of fatigue; 25% of patients had deterioration, and 
12% of patients had no change in fatigue scores at 6 months compared to baseline.  Reductions in 
fatigue did not correlate with reductions in CRP (r=-0.01; p=0.93), change in disease activity (r=0.13; 
p=0.17) or change in creatinine (r=0.01; p=0.65) or treatment allocation (p=0.68). 
Trajectory analysis
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One hundred and ten patients completed all four SF-36 questionnaires and 14 completed only 2 
SF36 questionnaires; 12 lacked 6 month data, 23 lacked 12 month data and 25 lacked 18 month 
data. GBTM identified four distinct groups of patients based on changes (or stability) of their fatigue 
scores during follow up (BIC all data points: -2369.1, BIC per participant: -2356.3) (figure 2). Model fit 
was further improved by refining the specification of the order polynomial for each trajectory (BIC all 
data points: -2348.3, BIC per participant: -2340.7). The four groups identified were:
 Stable low fatigue  – patients with low fatigue at trial entry who remained non-fatigued
 Stable high fatigue – patients with high fatigue at trial entry who remained fatigued
 High baseline fatigue improvers – patients with high fatigue at trial entry who improved over 
time
 Moderate baseline fatigue improvers – patients with moderate fatigue at trial entry who 
improved over time
The fatigue scores over time were compared within each GBTM group (table 2). The Stable low 
fatigue group (15%), reported median fatigue scores which were comparable to controls at baseline 
(stable low fatigue group median 70 (IQR 60-75) controls median 70 (IQR 55-80); p=0.77) and did not 
change over 18 months. In contrast, the Stable high fatigue group reported high median levels of 
fatigue at baseline median 30 (15-45) which did not improve over time. The Stable high fatigue 
group were more fatigued than the three other patient groups and controls at 18 months (Stable 
high fatigue median 30 (IQR 15-40), High baseline fatigue improvers median 55 (IQR 45-70), 
Moderate baseline fatigue improvers median 80 (IQR 70-85), Stable low fatigue median 65 (IQR 50-
70), controls median 70 (IQR 55-80); p<0.001).  In the six months following treatment initiation, the 
Moderate baseline fatigue improver group achieved a median reduction in fatigue of four times the 
MCID (baseline median 40 (IQR 30-49) vs 6 months median 80 (IQR 70-80)). The High baseline 
fatigue improver group achieved a less rapid, but continued fatigue improvement until month 12 
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(Table 2). However, at 18 months this group continued to have worse fatigue levels than controls 
(median 55 (IQR 45-70) vs median 70 (IQR 55-80); p<0.001).
Group characterisation sought to identify robust baseline markers which differentiated those who 
would remain fatigued (Stable high fatigue) from those who improved over time. This would allow 
early identification of those most in need of fatigue-specific interventions. Therefore, patients in the 
Stable high fatigue group were compared with the two groups of patients whose fatigue improved. 
Stable low fatigue patients were excluded as their fatigue levels were not different from controls at 
baseline. There were no differences in demographics variables between the three groups compared. 
Disease activity was lower in the Stable high fatigue group compared to the two groups whose 
fatigue improved (table 3). Additionally, there were no differences in the other SF-36 domains at 
baseline which differentiated the Stable high fatigue patients from the patients who improved (data 
not shown).
Stable high fatigue patients had lower BVAS scores at diagnosis compared to improvers. As there 
were no other demographic differences at diagnosis, we investigated whether there was any 
difference in time to remission or disease relapse over the first six months, as this was the period of 
fatigue improvement. Seven patients failed to achieve remission in the three fatigued groups; there 
were no differences in the time to remission (log rank=2 p=0.57) or relapse rates during follow up 
(table 3). At six months there were no differences between the three trajectory groups in renal 
function, damage (VDI) or inflammation levels (CRP).
Discussion
In this cohort of patients with incident AAV recruited to two clinical trials fatigue levels were worse 
than a control population. The extent and nature of the fatigue experienced by the patients in this 
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study is comparable with that reported in our previous studies(6) and in other rheumatological 
diseases. We have shown that, on average, fatigue responds well to treatment amongst AAV 
patients. However, using GBTM we identified important differences in an individual’s symptom 
change and identified a group of patients whose fatigue did not improve. In doing so, this study 
assessed the longitudinal response of fatigue in patients with AAV using trajectory analysis. We 
propose that such analytic approaches are crucial for patient-reported outcomes such as fatigue, 
which are  subjective and have a multi-factorial aetiology. This study provides patient level detail of 
the course of fatigue in AAV and information on the prognosis of fatigue, sorely needed by patients, 
identifying those who may require additional treatment focussed on fatigue rather than disease 
activity.
Patients in the Stable high fatigue group had lower levels of vasculitis activity at diagnosis (BVASv3 
score) compared to those whose fatigue improved over the first six months from diagnosis. Although 
the differences were statistically significant, there was considerable overlap in disease activity and 
fatigue between patient groups such that these factors did not predict, at an individual level, whose 
fatigue would fail to improve. It is unclear why those patients with High stable fatigue had lower 
disease activity compared to those patients who improved. There were no other disease 
characteristics that associated with persistent fatigue, specifically no association with renal function 
or inflammation. 
The lack of association with disease characteristics supports the suggestion that the aetiology of 
fatigue in these patients is multi-factorial and disease associated inflammation plays only a small 
part. . 
For patients in the High and Moderate baseline fatigue improver groups fatigue improved with 
treatment whereas for the other groups there was no change in fatigue despite treatment and 
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improvement in disease activity. Reductions in fatigue showed no association with change in C-
reactive protein, a surrogate marker of inflammation. Despite no difference in the percentage of 
patients in remission or disease activity at 6 months the trajectory of fatigue differed between the 4 
groups. Our original cross-sectional study showed only a small association of fatigue with 
inflammation. CRP was categorized as raised or normal and those with a raised CRP had a 3.7 odds 
ratio with wide confidence intervals (95% confidence intervals 1.7, 8.1)(10) and the population 
attributable risk was only 6%. Further, a recent publication looking at response of fatigue to 
treatment with anti-TNF medication suggested that most of the improvement was driven by 
improvements in pain(22). Others have also emphasized the importance of sleep in modifying 
fatigue and central pain processing(23)
 We and others have shown that  patient-reported domains such as pain, poor sleep and the ability 
to cope with illness may be more important in the development of fatigue in AAV(10) and other 
autoimmune conditions such as RA (24) than disease activity(25). Previous work in RA populations 
suggests that those with a history of depression are more likely to report greater fatigue in the 
future(26, 27). Our previous work has also suggested correlations between fatigue and anxiety and 
depression in patients with AAV (9), however this study was cross-sectional.  Given the substantial 
impact of fatigue on both patients and society, the results support the argument that fatigue is a 
symptom that must be targeted in its own right rather than being improved as part of a secondary 
benefit to existing interventions. 
There are several limitations to this study. The population included 150 patients and small effect 
sizes may have been missed. However this is a rare disease, it was an incident cohort, and data was 
collected prospectively. Interestingly, we have found that patients in the High stable fatigue group 
had lower disease activity than those whose fatigue improved. This has not been shown previously. 
The data collected was unable to explain this finding. We did not collect co-morbidity data, including 
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psychological co-morbidity, however, this was a more homogeneous population than other studies 
as all patients had new onset disease. It is recognised that these patients were recruited to clinical 
trials from secondary and tertiary care centres where clinicians are experienced in the management 
of AAV patients, which may affect patient reported outcomes. Despite 25% of our patients reporting 
a worsening of fatigue scores at six months we could not identify such a group using our trajectory 
analysis, suggesting the study may have been under-powered and needs repeating in a larger group. 
In addition, although the SF-36 vitality score is a valid tool for measuring fatigue(18, 19)  and has 
good psychometric properties(28), it may under-perform at higher levels of fatigue compared to 
other tools in some chronic diseases(29). Identification of those patients with a worse fatigue 
trajectory may require use of more sensitive fatigue measures.  Our study had a short follow up of 
only 18 months and it is unclear what happens to fatigue levels beyond this timeframe. However, we 
did note that fatigue levels in the patients who improved did not change between 12 and 18 months. 
Questionnaires were administered at 6 monthly intervals, which may have missed transitory changes 
in fatigue levels. However, we were interested in persistent chronic fatigue; the SF-36 Vitality 
domain has a recall of one month. 
In summary, the data suggest that fatigue is common in patients with AAV but average changes in 
fatigue are poorly informative of the variability in patterns of changes in fatigue over time.  The 
majority of patients presenting with AAV will experience fatigue which will improve but may not 
return to normal levels. In addition there is an important sub-group with high levels of fatigue at 
baseline who show no improvement in fatigue levels. These patients have lower levels of vasculitis 
activity at diagnosis. Further investigation of baseline differences in larger populations is required to 
understand this finding. Patients with persistent fatigue may be more likely to benefit from non-
pharmaceutical interventions addressing biopsychosocial symptoms such as pain, and social function 
strategies, which could be commenced at six months when patients are in remission. Further 
evaluation of such interventions is essential in order to address the unmet need of treatment for this 
important problem. 
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Figure Legends
Figure 1 Data presented as boxplots noting median, IQR and outliers of fatigue scores at each time 
point for all patients and healthy controls. The fatigue score is reverse scored with 0 indicating 
maximum fatigue and 100 indicating minimum fatigue.
0 p<0.001 fatigue score at time 0 compared with 6 months.
** p<0.001 time point compared with control
Figure 2
Trajectory analysis identified 4 distinct groups of patients based on changes (or stability) of their 
fatigue
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Tables 
Table 1 Patient Characteristics at baseline
controls n=470 Patients n=150 Significance
Age (years) 61.5 ± 13.6 57.9±17.5 p=0.002
Sex (m/f) 223/247 76/74 p=0.512
Trial (MYCYC/RITUXIVAS) 117/33
Diagnosis (MPA/GPA) 58/92
ANCA 
(MPO/PR3/negative/unknown)
54/90/3/2
VDI at diagnosis 0 (0-0)
Disease activity (BVASv3 score) 
at diagnosis
19 (13-24)
Creatinine at diagnosis 
(mol/L)
124 (80-231)
C-reactive protein (mg/L) 22 (7-72)
Fatigue 70 (55-80) 30 (10-48) p<0.001
Abbreviations: n, number; m, male; f, female; MYCYC, mycophenolate versus cyclophosphamide for 
induction therapy; RITUXVAS, rituximab versus cyclophosphamide for induction trial; MPA, 
microscopic polyangiitis; GPA, granulomatosis with polyangiitis; ANCA, anti-neutrophil cytoplasm 
antibody; MPO, myeloperoxidase; PR3, proteinase 3; VDI, vasculitis damage index; BVASv3, 
Birmingham vasculitis activity score version 2003. Median and IQR are shown apart from age (mean 
± SD).
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Table 2 Fatigue score of each GBTM group associated with time
Stable high 
fatigue
n=37
High baseline 
fatigue 
improvers
n=61
Moderate 
baseline 
fatigue 
improvers
n=29
Stable low 
fatigue
n=23
Controls
time 0 30 (15-45) 15 (5-25) 40 (30-49) 70 (60-75) 70 (55-80)
time 6 months 25 (15-40) 45 (40-55) 80 (70-80) 60 (50-65)
time 12 months 28 (20-40) 58 (50-66) 80 (75-90) 70 (50-80)
time 18 months 30 (15-40) 55 (45-70) 80 (70-85) 65 (50-70)
p value p=0.81 p<0.001 P<0.001 p=0.11
Fatigue score of each GBTM group associated with time. P values are derived from Friedman’s test 
for repeated measures for change in fatigue score over time within the GBTM group.
Abbreviations: n, number; GBTM, group-based trajectory modelling.  Data presented as median and 
IQR. 
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Table 3 Group Characteristics
Group
Stable high 
fatigue
High 
baseline 
fatigue 
improvers
Moderate 
baseline 
fatigue 
improvers
stable low 
fatigue
P value
n= 37 61 29 23
sex M/F
(M%)
18/19 
(49%)
31/30 
(51%)
14/15
 (48%)
13/10 
(56%)
0.966
diagnosis 
GPA/MPA
(%GPA)
20/17
(54%)
43/18
(70%)
16/12
(55%)
13/10
(56%)
0.179
trial 
MYCYC/RIT
UXVAS
(%MYCYC)
28/9 (75%) 50/11 (81%) 22/6 (76%) 17/6 (74%) 0.69
Treatment 
(MMF/CYC/
Rit)
14/18/5 27/25/9 7/16/6 10/9/4 0.46
Age (years) 62.0±18 55.3±17 55.8±18 61.8±15 0.201
BVAS at 
entry
14 (12-21) 21 (15-25) 20 (14-25) 18 (12-21) 0.014
BVAS at 6 
months
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0.15
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VDI at 6 
months
1 (0-2) 1 (0-2) 1 (0-2) 1 (0-2) 0.56
CRP at 
baseline 
(mg/L)
16 (4-88) 22 (8-61) 28 (8-90) 28 (6-78) 0.977
CRP at 6 
months 
(mg/L)
3 (1-7) 3.5 (1-7.6) 2.7 (1-4.2) 5 (2-18) 0.162
Creat at 
baseline 
(mol/l)
115 (67-
353)
119 (83-
209)
150 (92-
209)
116 (78-
223)
0.889
Creat at 6 
months 
(mol/l)
105 (70-
205)
98 (78-116)
106 (95-
126)
105 (87-
185)
0.451
Patients 
achieving 
remission 
(%)
35 (95%) 56 (92%) 27 (93%) 22 (96%) 0.708
Patients 
who 
relapsed (%)
15 (41%) 15 (25%) 6 (21%) 5 (22%) 0.213
Abbreviations: n, number; M, male; F, female; MYCYC, mycophenolate versus cyclophosphamide for 
induction therapy; RITUXVAS, rituximab versus cyclophosphamide for induction trial; CYC, 
cyclophosphamide; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; GPA, 
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granulomatosis with polyangiitis; BVAS, Birmingham vasculitis activity score version 2003. Median 
and IQR are shown apart from age (mean ± SD).
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Figure 1 
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Figure 2 
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